MARLBOROUGH, Mass.,
Aug. 3, 2015 /PRNewswire/ -- Boston
Scientific (NYSE: BSX) has become a significant shareholder and
will become the exclusive worldwide sales and marketing
representative for Preventice Solutions for cardiology-related
diagnostic and monitoring offerings.
Through this alliance, Boston Scientific will expand its
commercial presence into the $1
billion cardiac diagnostics and monitoring market by gaining
access to a wireless monitoring portfolio linked to an integrated
remote monitoring platform. This relationship with Preventice
Solutions reinforces Boston Scientific's commitment to
demonstrating the benefits of remote monitoring for a broad range
of patients.
Preventice Solutions, a privately held company, is a leading
developer of mobile health solutions and services and offers a full
portfolio of wearable cardiac monitors, including Holter monitors,
cardiac event monitors and mobile cardiac telemetry. These
technologies are complemented by monitoring services including data
transmission, surveillance, reporting, interpretation and
integration into a healthcare provider's workflow.
"As our healthcare environment continues to evolve, healthcare
practitioners, administrators and payors are looking for solutions
that identify relevant clinical insights from large volumes of
patient data and integrate those insights to improve clinical
decision-making," said Joe
Fitzgerald, executive vice president and president, Rhythm
Management, Boston Scientific. "This collaboration with Preventice
Solutions, which has an infrastructure optimized to monitor
hundreds of thousands of patients each year, is a critical step in
our effort to improve patient outcomes and reduce healthcare
costs."
Cardiac monitoring is a critical component required for the
diagnosis of many arrhythmias that require clinical intervention.
Preventice Solutions' portfolio includes the PatientCare Platform
and the BodyGuardian® family of products.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology
leader for more than 35 years, we advance science for life by
providing a broad range of high performance solutions that address
unmet patient needs and reduce the cost of healthcare. For more
information, visit www.bostonscientific.com and connect on Twitter
and Facebook.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like
"anticipate," "expect," "project," "believe," "plan," "estimate,"
"intend" and similar words. These forward-looking statements are
based on our beliefs, assumptions and estimates using information
available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements
include, among other things, statements regarding our business
plans and the strategic alliance with Preventice Solutions. If our
underlying assumptions turn out to be incorrect, or if certain
risks or uncertainties materialize, actual results could vary
materially from the expectations and projections expressed or
implied by our forward-looking statements. These factors, in some
cases, have affected and in the future (together with other
factors) could affect our ability to implement our business
strategy and may cause actual results to differ materially from
those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions; and
future business decisions made by us and our competitors. All
of these factors are difficult or impossible to predict accurately
and many of them are beyond our control. For a further list
and description of these and other important risks and
uncertainties that may affect our future operations, see Part I,
Item 1A – Risk Factors in our most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission, which
we may update in Part II, Item 1A – Risk Factors in
Quarterly Reports on Form 10-Q we have filed or will file
hereafter. We disclaim any intention or obligation to
publicly update or revise any forward-looking statements to reflect
any change in our expectations or in events, conditions or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary
statement is applicable to all forward-looking statements contained
in this document.
CONTACTS
Media:
Trish Backes
Boston Scientific Corporation
651-582-5887 (office)
Trish.Backes@bsci.com
Investors:
Susie Lisa, CFA
Boston Scientific Corporation
(508) 683-5565 (office)
investor_relations@bsci.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/boston-scientific-announces-equity-investment-and-sales-cooperation-agreement-with-preventice-solutions-300122635.html
SOURCE Boston Scientific Corporation